The obese transplant organ recipient: experimental and clinical evidence for tailored immunosuppression
Transplant International · 11.05.2026 · 39
DOI: 10.3389/ti.2026.16006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Transplant International, online erschienen am 11.05.2026. Verfasst von A Della Penna und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General, Visceral and Transplantation Surgery, University Hospital Tübingen, Tübingen, Germany. Hauptthemen laut MEDLINE: Obesity, Immunosuppressive Agents, Organ Transplantation, Immunosuppression Therapy. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Obesity has become a major determinant of outcomes across solid organ transplantation. Beyond its well-recognized metabolic and cardiovascular burden, obesity profoundly affects both immune regulation and the pharmacology of immunosuppressive therapy. Experimental evidence has established adipose tissue as an active immune organ that promotes low-grade inflammation through leptin, TNF-α, and IL-6, thereby altering alloimmune responses and impairing graft tolerance. Clinically, obesity is associated with increased surgical complications, delayed graft function, and reduced survival after kidney, liver, and thoracic organ transplantation. In parallel, obesity modifies drug disposition at every pharmacokinetic step, expanding the distribution volume for lipophilic agents such as calcineurin and mTOR inhibitors, altering CYP3A metabolism, and increasing interindividual variability in exposure. Consequently, both underexposure and toxicity remain frequent, underscoring the need for individualized therapeutic strategies. Current evidence supports the integration of therapeutic drug monitoring, pharmacogenomics, and biomarker-based approaches to refine immunosuppression intensity. This review summarizes experimental and clinical data linking obesity-induced inflammation with altered immunosuppressive pharmacology and proposes a framework for precision immunosuppression that balances efficacy, nephroprotection, and metabolic safety. Tailoring therapy to the specific immunometabolic profile of obese recipients may thus transform a major clinical challenge into an opportunity for precision transplant medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General, Visceral and Transplantation Surgery, University Hospital Tübingen, Tübingen, Germany.
- Department of Pharmacology, Experimental Therapy and Toxicology, Institute of Experimental and Clinical Pharmacology and Pharmacogenomics, University Hospital Tübingen, Tübingen, Germany.
- Hannover Medical School, Department of General, Visceral and Transplant Surgery, Hannover, Germany.
Zitieren
APA
Della Penna, A., Beer-Hammer, S., Nadalin, S., Capobianco, I., Felgendreff, P., Schmelzle, M., & Quante, M. (2026). The obese transplant organ recipient: experimental and clinical evidence for tailored immunosuppression. Transplant International, 39. https://doi.org/10.3389/ti.2026.16006
Vancouver
Della Penna A, Beer-Hammer S, Nadalin S, Capobianco I, Felgendreff P, Schmelzle M, et al. The obese transplant organ recipient: experimental and clinical evidence for tailored immunosuppression. Transplant International. 2026;39. doi:10.3389/ti.2026.16006
BibTeX
@article{DellaPenna2026,
author = {Della Penna, A and Beer-Hammer, S and Nadalin, S and Capobianco, I and Felgendreff, P and Schmelzle, M and Quante, M},
title = {The obese transplant organ recipient: experimental and clinical evidence for tailored immunosuppression},
journal = {Transplant International},
year = {2026},
volume = {39},
doi = {10.3389/ti.2026.16006}
}
EUVIMED